Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Platform Trial of Long-acting Antibodies in Moderately to Severely Active Ulcerative Colitis
jRCT2031260002Phase 2Not yet recruiting
- Sponsor
- Spyre Therapeutics, Inc.
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of SPY001, SPY002 and SPY003 in autoimmune colitis (10 arms), sponsored by Spyre Therapeutics, Inc. Primary endpoint: Clinical remission at Week 12. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
SPY001SPY002SPY003
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2031260002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260002.